Meningococcal meningitis and septicaemia is a rare but potentially devastating and unpredictable bacterial infection. 1 While meningococcal disease mainly affects children below the age of five and adolescents, it can affect healthy individual at any age. 1,2 The disease can claim a life in as little as 24 hours or cause severe long-term sequelae (such as hearing loss, brain damage and disability) with devastating effects on the individuals and their families. 3,4
At Sanofi Pasteur, we believe in a world where no one suffers or dies from vaccine preventable diseases. For over 45 years, we have been at the forefront in combating meningococcal epidemics and in driving meningococcal vaccine evolution, to further expand protection of individuals worldwide.
Sumeyra - Meningococcal disease survivor
Routine Vaccination Programs
Sanofi Pasteur’s legacy
References
- European Centre for Disease Prevention and Control (ECDC). Surveillance Atlas of Infectious Diseases. Available at https://www.ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/atlas [accessed November 2020].
- WHO. Meningococcal meningitis https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis [accessed November 2020].
- Beebeejaun, K et al. Invasive meningococcal disease: Timing and cause of death in England, 2008–2015. Journal of Infection, March 2020 https://doi.org/10.1016/j.jinf.2019.12.008 [accessed November 2020].
- Meningitis Research Foundation. After effects https://www.meningitis.org/meningitis/after-effects [accessed November 2020].
- Sanofi Pasteur (2020). Meningococcal Disease in Europe: A Rare but Devastating Disease.